Market open
Plus Therapeutics Inc./$PSTV
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Plus Therapeutics Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Ticker
$PSTV
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
21
ISIN
US72941H5090
Website
PSTV Metrics
BasicAdvanced
$12M
-
-$1.95
0.67
-
Price and volume
Market cap
$12M
Beta
0.67
52-week high
$2.31
52-week low
$0.24
Average daily volume
2.8M
Financial strength
Current ratio
0.338
Quick ratio
0.269
Long term debt to equity
-0.346
Total debt to equity
-37.624
Interest coverage (TTM)
-3.95%
Management effectiveness
Return on assets (TTM)
-101.93%
Return on equity (TTM)
252.07%
Valuation
Price to revenue (TTM)
0.796
Price to book
-0.46
Price to tangible book (TTM)
-0.42
Price to free cash flow (TTM)
-0.412
Growth
Revenue change (TTM)
18.54%
Earnings per share change (TTM)
-44.80%
3-year earnings per share growth (CAGR)
-48.00%
PSTV News
AllArticlesVideos
Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)
GlobeNewsWire·2 hours ago
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors
GlobeNewsWire·3 weeks ago
Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Plus Therapeutics Inc. stock?
Plus Therapeutics Inc. (PSTV) has a market cap of $12M as of May 14, 2025.
What is the P/E ratio for Plus Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Plus Therapeutics Inc. (PSTV) stock is 0 as of May 14, 2025.
Does Plus Therapeutics Inc. stock pay dividends?
No, Plus Therapeutics Inc. (PSTV) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next Plus Therapeutics Inc. dividend payment date?
Plus Therapeutics Inc. (PSTV) stock does not pay dividends to its shareholders.
What is the beta indicator for Plus Therapeutics Inc.?
Plus Therapeutics Inc. (PSTV) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.